Intelligent Bio Solutions Inc. (NASDAQ: INBS) made waves in the market back in mid-2024 when it completed crucial in-clinic testing as part of its FDA 510(k) submission process. This wasn’t just another run-of-the-mill test; it was a pivotal moment for validating their unique drug-testing approach using sweat analysis, and traders were already picking up the buzz.
Pharmacokinetic Study Results: A New Benchmark?
The pharmacokinetic (PK) study wrapped up with some significant findings that had desks re-evaluating their positions. Involving 135 participants across three locations, the study aimed to prove that measuring drugs in fingerprint sweat could either match or beat traditional methods like blood, saliva, and urine tests. You can bet traders were eyeing this data closely—after all, if INBS's method holds up against lab standards, it might just redefine drug screening.
This kind of non-invasive option for drug screening could cater to various sectors.
Harry Simeonidis, the President and CEO, highlighted that reaching this milestone brought them closer to gaining FDA clearance—a move that could catapult INBS into the limelight. Initial feedback from early adopters indicated that this fingerprint-based method may be a reliable alternative in industries where safety is crucial.
Next Steps: Preparing for Market Launch
As they strategized on their FDA submission plan moving forward, there was a palpable sense of urgency around the trading desks. Detailed clinical data analysis was expected to wrap by late 2024, with hopes to submit the application around then too. But will investors hold strong through these delays? That's always a dicey proposition when markets are thirsty for action.
This groundbreaking technology allows rapid results—under ten minutes—and is currently making headway internationally, primarily serving industries like construction and transport where rapid responses can mean life or death scenarios. But while they’re expanding globally, how will INBS manage their domestic rollout? The pressures are mounting.